I have been looking for ADXS action lately. Good swings if you have stomach for it. Near-term target $1.20
Long term The company has cash into 2022. A few catalysts
ADXS-HOT: Off-the-shelf, tumor type-specific constructs ADXS-503 in NSCLC in Phase 1/2 study ADXS-504 in prostate cancer scheduled to enter the clinic in Q1 2021
Forthcoming Milestones
*ADXS-503: Phase 1/2 combination with KEYTRUDA--clinical and immune/biomarker data for KEYTRUDA failures as well as first-line patients ADXS-504: Clinical trial initiation; initial data readout ADXS-PSA: Announcement of next steps
The first patient dosed with HOT-Prostate by Q1 2021
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.